Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1990 Oct;82(1):75–80. doi: 10.1111/j.1365-2249.1990.tb05406.x

Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease.

Y R Mahida 1, A Gallagher 1, L Kurlak 1, C J Hawkey 1
PMCID: PMC1535179  PMID: 2208797

Abstract

Plasma and tissue interleukin-2 receptor (IL-2R) levels were determined in patients with active ulcerative colitis and Crohn's disease. Compared with healthy controls (median 440 U/ml; range 240-900), significantly higher levels of plasma IL-2R were present in patients with active ulcerative colitis (median 1180 U/ml; range 580-7150; P less than 0.002) and Crohn's disease (median 1340 U/ml; range 480-9000; P less than 0.002). Compared with other laboratory parameters, plasma IL-2R levels were related most closely to clinical score of disease activity in Crohn's disease. Plasma IL-2R levels also reflected the clinical course and may provide a more accurate assessment of disease activity in Crohn's disease. In plasma of patients undergoing intestinal resection of active inflammatory bowel disease, raised levels of IL-2R were present in samples from mesenteric vein (draining inflamed intestine) compared with those from peripheral vein. In tissue homogenates of colonic biopsies, significantly higher levels of IL-2R were present in specimens from colons with active ulcerative colitis compared with healthy controls (median 230.2, range 20.7-581.5 versus 77.9, range 34.2-291.3; P less than 0.02).

Full text

PDF
78

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARON J. H., CONNELL A. M., LENNARD-JONES J. E. VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS. Br Med J. 1964 Jan 11;1(5375):89–92. doi: 10.1136/bmj.1.5375.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Colver G. B., Symons J. A., Duff G. W. Soluble interleukin 2 receptor in atopic eczema. BMJ. 1989 May 27;298(6685):1426–1428. doi: 10.1136/bmj.298.6685.1426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Duff G. W. Peptide regulatory factors in non-malignant disease. Lancet. 1989 Jun 24;1(8652):1432–1435. doi: 10.1016/s0140-6736(89)90134-7. [DOI] [PubMed] [Google Scholar]
  4. Ebert E. C., Wright S. H., Lipshutz W. H., Hauptman S. P. T-cell abnormalities in inflammatory bowel disease are mediated by interleukin 2. Clin Immunol Immunopathol. 1984 Nov;33(2):232–244. doi: 10.1016/0090-1229(84)90078-3. [DOI] [PubMed] [Google Scholar]
  5. Fiocchi C., Hilfiker M. L., Youngman K. R., Doerder N. C., Finke J. H. Interleukin 2 activity of human intestinal mucosa mononuclear cells. Decreased levels in inflammatory bowel disease. Gastroenterology. 1984 Apr;86(4):734–742. [PubMed] [Google Scholar]
  6. Harvey R. F., Bradshaw J. M. A simple index of Crohn's-disease activity. Lancet. 1980 Mar 8;1(8167):514–514. doi: 10.1016/s0140-6736(80)92767-1. [DOI] [PubMed] [Google Scholar]
  7. Mahida Y. R., Patel S., Wu K., Jewell D. P. Interleukin 2 receptor expression by macrophages in inflammatory bowel disease. Clin Exp Immunol. 1988 Dec;74(3):382–386. [PMC free article] [PubMed] [Google Scholar]
  8. O'Callaghan C., Franklin P., Elliott T. S., Deverill I., Richards N., Powell R. J. C reactive protein concentrations in neonates: determination by a latex enhanced immunoassay. J Clin Pathol. 1984 Sep;37(9):1027–1028. doi: 10.1136/jcp.37.9.1027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. O'Garra A. Interleukins and the immune system 1. Lancet. 1989 Apr 29;1(8644):943–947. [PubMed] [Google Scholar]
  10. Pallone F., Fais S., Squarcia O., Biancone L., Pozzilli P., Boirivant M. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut. 1987 Jun;28(6):745–753. doi: 10.1136/gut.28.6.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Powell-Tuck J., Bown R. L., Lennard-Jones J. E. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13(7):833–837. doi: 10.3109/00365527809182199. [DOI] [PubMed] [Google Scholar]
  12. Raedler A., Fraenkel S., Klose G., Seyfarth K., Thiele H. G. Involvement of the immune system in the pathogenesis of Crohn's disease. Expression of the T9 antigen on peripheral immunocytes correlates with the severity of the disease. Gastroenterology. 1985 Apr;88(4):978–983. doi: 10.1016/s0016-5085(85)80017-2. [DOI] [PubMed] [Google Scholar]
  13. Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985 Nov;135(5):3172–3177. [PubMed] [Google Scholar]
  14. Trowbridge I. Interleukin-2 receptor proteins. Nature. 1987 Jun 11;327(6122):461–462. doi: 10.1038/327461b0. [DOI] [PubMed] [Google Scholar]
  15. Wood N. C., Symons J. A., Duff G. W. Serum interleukin-2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity? J Autoimmun. 1988 Aug;1(4):353–361. doi: 10.1016/0896-8411(88)90005-4. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES